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Most patients with early stage triple negative breast cancer (TNBC) receive adjuvant che-
motherapy. Activation of the immune system is associated with tumor response and may
help identify TNBC with favorable outcome.
Methods
Gene expression data were obtained from the GEO Dataset GDS2250/GSE3744. Affyme-
trix CEL files were downloaded and analyzed with Affymetrix Transcriptome Analysis Con-
sole 3.0. Functional genomics was implemented with David Bioinformatics Resources 6.8.
Data contained at Oncomine were used to identify genes upregulated in basal-like cancer
compared to normal breast tissue. Data contained at cBioportal were used to assess for
molecular alterations. The KMPlotter online tool, METABRIC and GSE25066 datasets were
used to associate gene signatures with clinical outcome.
Results
1564 upregulated genes were identified as differentially expressed between normal and
basal-like tumors. Of these, 16 genes associated with immune function were linked with clin-
ical outcome. HLA-C, HLA-F, HLA-G and TIGIT were associated with both improved
relapse-free survival (RFS) and overall survival (OS). The combination of HLA-F/TIGIT
and HLA-C/HLA-F/TIGIT showed the most favorable outcome (HR for RFS 0.44, p<0.001;
HR for OS 0.22, p<0.001; and HR for RFS 0.46, p<0.001; HR for OS 0.15, p<0.001;
respectively). The association of HLA-C/HLA-F with outcome was confirmed using the
METABRIC and GSE25066 datasets. No copy number alterations of these genes were
identified.
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Conclusion
We describe a gene signature associated with immune function and favorable outcome in
basal-like breast cancer. Incorporation of this signature in prospective studies may help to
stratify risk of early stage TNBC.
Introduction
Metastatic triple negative breast cancer (TNBC) is an incurable disease [1]. However, in early
stage disease, surgical resection and adjuvant treatment with chemotherapy can contribute to
cure in a substantial proportion of patients [1].
Decisions for recommendation for adjuvant treatment in breast cancer are based on the
overall risk of cancer recurrence which can be estimated based on the extent of disease, as well
as biological factors such as histologic grade and receptor status. For TNBC given the high risk
of relapse and the poor prognosis, treatment with chemotherapy is offered to most patients.
However, in some circumstances the benefit from adjuvant chemotherapy in TNBC can be
less clear, for instance when tumors are very small, when patients are older or when medical
co-morbidities make the toxicity of chemotherapy less favorable [2]. In these circumstances it
would be desirable to have better information about prognosis.
Inhibition of immune surveillance is one of the hallmarks of cancer [3]. Activation of
immune system against the tumor can lead to an anti-tumor response and therefore potentially
improve clinical outcome. In TNBC the presence of tumor infiltrating lymphocytes (TIL) is a
marker of the activation of the immune system and is associated with improved outcome
[4, 5]. Indeed, therapeutic strategies to activate the immune system, like those blocking the
programmed death receptor-1 (PD-1) or its ligand; or cytotoxic T-lymphocyte associated pro-
tein 4 (CTLA-4) receptors, have shown activity in several solid tumors [6]. In TNBC these
agents are currently in late stages of development [7].
Different cell membrane proteins are associated with the identification of neoantigens and
activation of effector T-cells, or the regulation of this activation [8]. This has been the case for
antibodies against PD1 and CTLA4, among others [8]. However, many other cell surface regu-
lators involved in this activation exist and have not been explored. An example includes the
family of Human Leucocyte Antigens (HLA), or the novel regulatory protein T cell immunore-
ceptor with Ig and ITIM domains (TIGIT) [9].
In our study, by using an in silico approach, we aimed to identify genes that code for cell
surface proteins and then select those involved in the regulation of the immune system for fur-
ther evaluation. We subsequently examined their prognostic influence to help identify patients
at lower risk of relapse and for whom treatment with chemotherapy may not be needed.
Material and methods
Transcriptomic and gene-set enrichment analyses
We used a public dataset (GEO DataSet accession number: GDS2250) [10] of mRNA level
data from normal breast tissue and basal-like breast tumors to identify upregulated genes.
Affymetrix CEL files were downloaded and analyzed with Affymetrix Transcriptome Analysis
Console 3.0. We obtained genes with different expression values from the two samples and
unregulated genes were defined as those with a minimum 2 fold differential expression
between normal and malignant tissue. We selected this cut-off level to include a large number
Transcriptomic immunologic signature associated with clinical outcome in basal-like breast tumors
PLOS ONE | https://doi.org/10.1371/journal.pone.0175128 May 4, 2017 2 / 10
Competitiveness of Spain (BFU2015-71371-R), the
Instituto de Salud Carlos III through the Spanish
Cancer Centers Network Program (RD12/0036/
0003) and CIBERONC, the scientific foundation of
the AECC and the CRIS Foundation (to AP). The
work carried out in our laboratories received
support from the European Community through
the regional development funding program
(FEDER). The funders had no role in study design,
data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing interests: The authors have declared
that no competing interests exist.
of genes. The list of genes was analyzed using gene-set enrichment analyses using DAVID Bio-
informatics Resources 6.8 (https://david.ncifcrf.gov/) in order to identify functions of these
genes. We used an adjusted p-value of less than 0.05 to select the enriched gene sets. Data con-
tained at Oncomine (www.oncomine.org) was used to independently confirm the difference
among the selected genes.
Outcome analyses
The KM Plotter Online Tool was used to analyze the relationship between the gene expression
and patient clinical outcome in breast cancer (http://www.kmplot.com); this public database
allowed us to investigate overall survival (OS) and relapse-free survival (RFS) [11]. Definitions
of breast cancer subgroups reported in this online tool are: triple negative (ER-/HER2-), lumi-
nal A (ESR1+/HER2-/MK167-low), luminal B (ESR1+/HER2-/MK167-high or ESR1+/HER2
+), and basal-like (ESR1-/HER2-) [12]. Analysis was carried out in multiple steps. First, we
restricted analysis to the basal-like breast cancer subgroup. Then, the association between the
genes of interest and outcome was explored after selection of the specific probe utilized ini-
tially. Finally, we evaluated all immunologic-related genes and their association with both RFS
and OS in basal like breast cancer, and confirmed these data in the Oncomine dataset.
We also confirmed the results using two additional datasets: METABRIC [13] and the
GSE25066 dataset [14]. METABRIC contains information about 331 basal-like tumors with
data available for OS, while the GSE25066 dataset comprises RFS data on 142 basal-like
tumors.
Evaluation of molecular alterations
To explore the presence of mutations, deletions or amplifications in the identified genes we
used data contained at cBioportal (www.cbioportal.org) [15].
Results
Identification of upregulated genes coding for membrane cell surface
proteins
To identify upregulated genes in TNBC we analyzed data from a public GEO Dataset (acces-
sion number: GDS2250/GSE3744) [10]. Using a minimum fold change of 2, we selected 1564
upregulated genes. We evaluated these genes using functional genomics with David Bioinfor-
matics Resources 6.8 (https://david.ncifcrf.gov/). As genes that code for proteins that are at the
plasma membrane can be involved in several functions we extracted different functions
including cell differentiation, communication, adhesion, transmembrane transport and trans-
membrane receptor tyrosine kinase signaling pathway (Fig 1A). A total of 934 genes were
included in these functions (S1 Table).
Selection of immune genes linked with outcome
Using information from genes that code for proteins at the cell membrane, we explored only
those involved in immunological processes that are associated with outcome, and confirmed
their upregulated expression in breast cancer using data available at Oncomine (Fig 1B and
S2 Table). A total of 16 genes were identified, but only ten confirmed as upregulated using
data from Oncomine and linked with outcome. Using the online tool KM plotter [11] and
making the analyses for those ten genes we observed that, CD300A, CD6, DAPP1, TLR6,
CSF2RA and BTN2A2 were associated with improved RFS only, while HLA-C, HLA-F,
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HLA-G and TIGIT were associated with both improved RFS and OS in basal breast cancer
patients (Fig 1B).
Gene set combinations for HLA-C, HLA-F, HLA-G and TIGIT
Table 1 shows the association of all the immunologic-related genes with RFS and OS. TIGIT
was the gene associated with the best outcome (HR 0.36 [95% CI 0.25–0.52]; p<0.001 for RFS
and HR 0.37 [95% CI 0.16–0.84]; p = 0.01 for OS). Table 2 shows results for the combinations
of HLA-C, HLA-F, HLA-G and TIGIT as predictors of patient outcome. The combination of
HLA-F and TIGIT, and HLA-C, HLA-F and TIGIT were the two best combinations for clini-
cal outcome. HLA-F and TIGIT (HR for RFS 0.44 [95% CI 0.31–0.63] p<0.001 and HR for OS
0.22 [95% CI 0.09–0.55) p<0.001, see Fig 2). For HLA-C, HLA-F and TIGIT, the HR for RFS
was 0.46 [95% CI 0.32–0.65] p<0.001 and HR for OS 0.15 [95% CI 0,05–0,44] p<0.001, see
Fig 3). Although the analysis was done using the median, the correlation between survival and
the combined gene signature was independent of the used cutoff value for both RFS and OS
(S1 Fig).
Fig 1. Gene-set enrichment analyses of differentially expressed genes between normal breast and basal like breast cancer, and association with
clinical outcome. A. Overexpressed genes with a minimum of two fold-change difference between normal breast and basal-like breast cancer (left side), as
described in material and methods. Using functional annotation, only genes associated with functions linked with cell membrane proteins were included (right
side). B. Identification of immunologic related genes included in the identified functions (16 genes). Selection of genes which upregulation was confirmed
using data contained at Oncomine (10 genes) and linked with outcome. Outcome screening analyses for RFS and OS using the KMplotter online tool for those
ten identified genes.
https://doi.org/10.1371/journal.pone.0175128.g001
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HLA-C, HLA-F, HLA-G and TIGIT were not associated with mutations or copy number
gains (S3 Table). The specific function of these genes is described in S4 Table.
Confirmation of gene signatures with outcome
To confirm the association of these gene signatures with outcome we used additional public
available databases. The METABRIC database [13] contains information on OS in 331 basal-
like tumors. Of note the TIGIT gene is not included in this database. Fig 4A shows results asso-
ciated with outcome. The combination of HLA-C and HLA-F was associated with the better
outcome (HR 0.54 [95% CI 0.36–0.80] p = 0.002. Using the GSE25066 dataset [14] that con-
tains RFS data in 142 basal-like patients, the combination of HLA-C and HLA-F showed
improved RFS (HR 0,45 [95% CI 0.23–0.90] p = 0.02), confirming the results previously
described (Fig 4B). Again this dataset did not include TIGIT.
Table 1. List of the identified immunologic-related genes associated with RFS and OS in basal like breast cancer.
Probe Set Gene name Basal Like
Relapse Free Survival Overall Survival
HR (Hazard Ratio) Logrank
P-value
HR (Hazard Ratio) Logrank P-
value
217072_at CD300A, CD300a molecule 0,74 (0,57–0,96) 0,023 - >0,05
211893_x_at CD6, CD6 molecule 0,53 (0,4–0,69) 2,20E-06 - >0,05
222859_s_at DAPP1, dual adaptor of phosphotyrosine and 3-phosphoinositides 0,5 (0,35–0,7) 5,50E-05 - >0,05
211799_x_at HLA-C, major histocompatibility complex, class I, C 0,59 (0,45–0,77) 9,90E-05 0,38 (0,21–0,71) 0,0014
221875_x_at HLA-F, major histocompatibility complex, class I, F 0,53 (0,41–0,7) 2,80E-06 0,35 (0,19–0,63) 0,00032
211528_x_at HLA-G, major histocompatibility complex, class I, G 0,6 (0,46–0,79) 0,00017 0,42 (0,23–0,75) 0,0028
239021_at TLR6, toll-like receptor 6 0,67 (0,48–0,95) 0,023 - >0,05
210340_s_at CSF2RA, colony stimulating factor 2 receptor, alpha, low-affinity
(granulocyte-macrophage)
0,59 (0,45–0,76) 6,80E-05 - >0,05
240070_at TIGIT, T cell immunoreceptor with Ig and ITIM domains 0,36 (0,25–0,52) 8,30E-09 0,37 (0,16–0,84) 0,014
1564684_at BTN2A2, butyrophilin, subfamily 2, member A2 0,55 (0,39–0,78) 0,00072 - >0,05
https://doi.org/10.1371/journal.pone.0175128.t001
Table 2. List of gene combinations associated with favorable outcome in basal like cancer using the KM plotter online tool, as described in mate-
rial and methods.
Gene combinations Relapse Free Survival Overall Survival
HR (Hazard Ratio) Logrank P- value N (patients) HR (Hazard Ratio) Logrank P- value N (patients)
HLA-C, HLA-F, HLA-G, TIGIT 0,54 (0,38–0,77) 0.00047 339 0,2 (0,08–0,54) 0,00036 132
HLA-C, HLA-F, HLA-G 0,55 (0,42–0,72) 7,8E-06 580 0,38 (0,21–0,7) 0,0011 204
HLA-C, HLA-F, TIGIT 0,46 (0,32–0,65) 7,5E-06 339 0,15 (0,05–0,44) 6,2E-05 132
HLA-C, HLA-G, TIGIT 0,56 (0,4–0,79) 0,00081 339 0,15 (0,05–0,44) 6,7E-05 132
HLA-F, HLA-G, TIGIT 0,5 (0,35–0,71) 7,8E-05 339 0,25 (0,1–0,62) 0,0012 132
HLA-C, HLA-F 0,51 (0,39–0,67) 6,2E-07 580 0,31 (0,16–0,58) 0,00011 204
HLA-C, HLA-G 0,62 (0,47–0,8) 0,00029 580 0,39 (0,21–0,71) 0,0014 204
HLA-C, TIGIT 0,58 (0,41–0,81) 0,0015 339 0,21 (0,08–0,57) 0,00063 132
HLA-F, HLA-G 0,57 (0,44–0,75) 3,5E-05 580 0,42 (0,23–0,76) 0,0029 204
HLA-F, TIGIT 0,44 (0,31–0,63) 3E-06 339 0,22 (0,09–0,55) 0,00037 132
HLA-G, TIGIT 0,57 (0,4–0,81) 0,0013 339 0,19 (0,07–0,51) 2E-04 132
https://doi.org/10.1371/journal.pone.0175128.t002
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Fig 2. Association of the combined analyses of HLA-F and TIGIT with RFS and OS in basal-like patients using the KM plotter online tool, as
described in material and methods.
https://doi.org/10.1371/journal.pone.0175128.g002
Fig 3. Association of the combined analyses of HLA-F, HLA-C and TIGIT with RFS and OS in basal-like patients using the KM plotter online tool, as
described in material and methods.
https://doi.org/10.1371/journal.pone.0175128.g003
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Discussion
In our study we intended to explore cell surface transmembrane proteins linked with immuno-
logical function and outcome. Cell membrane proteins can easily be used as biomarkers and
potentially as therapeutic targets. We found that genes that code for membrane receptors
involved in the identification of antigens and regulation of immune response were associated
with good prognosis. HLA-C, HLA-F, HLA-G and TIGIT are frequently overexpressed in
TNBC compared with normal breast and associated with improved RFS and OS in different
datasets.
Using data contained at KM Plotter we observed that HLA-C, HLA-F, HLA-G and TIGIT
were associated with good prognosis. Studies in which we used combinations of these genes
particularly for HLA-C and HLA-F or HLA-C, HLA-F and TIGIT showed association with
good prognosis. We confirmed data for HLA-C and HLA-F combination in two independent
datasets, (METABRIC and GSE25066). Unfortunately, TIGIT was not included in either
dataset.
Recognition of antigens and activation of T-Cells is a key function in the immune
response to cancer [8]. Indeed, hosts that can recognize tumor cells and activate an effector
response are those linked with a better outcome. This has been observed when evaluating
the association of TIL with outcome, a positive association which has been observed in
TNBC [4, 5]. Our data are consistent with this. In addition, the fact that no copy number
alterations exist, suggest that upregulation of these genes occurs due to the activation of an
immune response.
HLA comprises a set of surface proteins whose main function is to display antigens on the
cell surface of antigen presenting cells (APCs) for the recognition by T-cells [8]. TIGIT is a
Fig 4. A. Association of the combined analyses of HLA-F and HLA-C with OS by using data available in METABRIC. B. Association of the combined
analyses of HLA-F and HLA-C with RFS by using data available in GSE25066.
https://doi.org/10.1371/journal.pone.0175128.g004
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recently discovered immune receptor expressed in T cells and natural killers (NK) [9]. TIGIT
has been described as overexpressed in CD8 expressing TILs in melanoma [16].
Although most patients with early stage triple negative breast cancer receive treatment with
chemotherapy due to the high risk of relapse of this disease, there is a small number of patients
for whom decisions are less clear [17].
This includes patients with small tumors, older patients or those with comorbidities. In this
subgroup, additional information such as whether an immune response is anticipated could be
valuable. Moreover, the possibility of using agents that may modulate TIGIT activity can also
be explored as a therapeutic strategy.
This study has a few limitations. This is an in silico and exploratory analysis that needs con-
firmation in larger studies. In addition, it would be interesting to study whether HLA-C,
HLA-F and TIGIT expression is associated with quantitative intra-tumoral TILs.
In conclusion, using three independent datasets, we describe an immunologic signature
associated with good outcome in TNBC patients. This signature can be considered as expres-
sion of an immunologic response composed of genes associated with the presentation of anti-
gens and the regulation of the immune response. Further studies should be performed to
confirm the prognostic value in prospective studies.
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